Data from IQVIA showed that Celltrion's autoimmune treatment Remsima (infliximab) held the top prescription spot across all four markets as of the third quarter of 2025, capturing 93 percent of the market in Singapore, 77 percent in Hong Kong, 73 percent in Thailand and 65 percent in Malaysia.
The company's oncology portfolio has also gained considerable traction.
Breast and gastric cancer treatment Herzuma (trastuzumab) secured market shares of 87 percent in Thailand, 57 percent in Hong Kong and 51 percent in Malaysia, while blood cancer drug Truxima (rituximab) held 90 percent in Singapore and 79 percent in Thailand — all ranking first in their respective categories.
In Singapore, Celltrion's adalimumab biosimilar Yuflyma has overtaken the original biologic to claim the second-highest market share. The company's Singapore unit plans to roll out a 20mg dosage of Yuflyma alongside the existing 40mg option ahead of upcoming adalimumab tenders, aiming to widen its competitive edge. Celltrion has also launched Yuflyma in Malaysia and Thailand.
Celltrion's Thai subsidiary has forged long-term partnerships with every university hospital in the country, where Remsima, Truxima and Herzuma are now used as the sole biosimilar in each of their categories.
The firm is broadening its product lineup across the region, with plans to secure approval for Stoboclo-Osenvelt (denosumab) in Singapore this year and to introduce three new products — Steqeyma (ustekinumab), Vegzelma (bevacizumab) and Omlyclo (omalizumab) — in Thailand.
"We are elevating prescription outcomes on the back of product competitiveness and supply stability in Asia's tender-driven markets, and positive perceptions of Celltrion products are spreading rapidly," a company spokesperson said.
"We will devote our full efforts to deepening the performance of existing products while ensuring the timely launch of new ones."
Copyright ⓒ Aju Press All rights reserved.